Standalone DTx: clinical and economic evidence

As DTx companies look for their place in the market, in order to convince the different healthcare stakeholders (payers, physicians, etc), they need to generate clinical and economic data that validates their products and services. The evidence requirements and challenges to generate it differ depending on the type of DTx; on this occasion we will focus on standalone DTx (DTx products used independently of drugs). Join this informal conversation with other senior leaders in the space to discuss the following: